Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is skin cancer: non-melanoma vs. melanoma?
Skin cancer happens when skin cells grow out of control, usually after years of sun (ultraviolet) exposure. The two most common kinds — basal cell carcinoma and squamous cell carcinoma — are grouped as 'non-melanoma' skin cancer. They grow slowly, rarely spread, and are highly curable. Melanoma is less common but more serious because it can spread if not caught early. Most skin cancers appear on sun-exposed areas like the face, ears, scalp, and hands.
The main types
Doctors group skin cancer: non-melanoma vs. melanoma by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| Basal cell carcinoma (BCC) | The most common skin cancer. Grows slowly, almost never spreads, but can damage nearby tissue if ignored. |
| Squamous cell carcinoma (SCC) | Second most common. Usually curable, but slightly more likely than BCC to spread if neglected. |
| Melanoma | Less common but more dangerous; develops in pigment cells and can spread, so early detection is key. |
| Precancers (actinic keratoses) | Rough, scaly sun-damage spots that can turn into squamous cell cancer and are easily treated early. |
Staging, in plain terms
Skin cancers are staged with TNM (tumor size/depth, lymph nodes, metastasis). For the common non-melanoma types, most are found very early — small and confined to the skin — so high stages are uncommon. Melanoma staging also weighs how deeply the tumor has grown (thickness).
| TNM | What it generally means |
|---|---|
| Stage 0 | Earliest form (in situ) — abnormal cells only in the top layer of skin. Essentially 100% curable. |
| Stage I | A small tumor confined to the skin with no high-risk features. Very high cure rate. |
| Stage II | A larger or higher-risk tumor still limited to the skin. |
| Stage III | Has reached nearby lymph nodes or deeper structures. |
| Stage IV | Spread to distant sites — uncommon for basal and squamous cell cancers. |
The standard of care
Skin Cancer: Non-Melanoma vs. Melanoma is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Surgery / Mohs
Cutting out the cancer; Mohs surgery removes it layer by layer to spare healthy skin, often used on the face.
Radiation therapy
A non-surgical cure that's ideal when surgery would be disfiguring, in delicate areas (nose, ear, eyelid), or for patients who prefer to avoid an incision.
Topical & local treatments
Creams, freezing (cryotherapy), or light-based therapy for very early or superficial lesions and precancers.
Medicines (advanced cases)
Immunotherapy or targeted drugs for the rare cancers that spread or can't be removed.
How radiation treatment works
Radiation uses focused energy to damage the DNA of cancer cells so they stop dividing and die off, while healthy skin gradually repairs and renews itself. For common skin cancers, low-energy superficial radiation stays near the surface where the cancer lives, avoiding deeper tissue. Image guidance with ultrasound lets the team see the tumor's depth and confirm it's fully treated. Sessions are painless and brief, and because there's no cutting, there's no surgical scar — a meaningful advantage on the face.
The main ways radiation is delivered for skin cancer: non-melanoma vs. melanoma:
Image-guided superficial radiation therapy (IG-SRT)
Combines high-resolution ultrasound imaging with gentle, low-energy radiation to treat the tumor precisely while sparing deeper tissue — scar-free, no cutting, and reported up to ~99% effective for selected non-melanoma cancers.
External-beam radiation
Shaped beams treat larger or deeper tumors, or lymph node areas, over several short sessions.
Brachytherapy (surface)
A custom applicator delivers radiation right at the skin surface, useful for curved areas like the nose or ear.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
IG-SRT as a first-line option (2025): An expert dermatology panel in SKIN: The Journal of Cutaneous Medicine concluded image-guided superficial radiation is safe, effective, and can be a first-line treatment for appropriately selected non-melanoma skin cancers, with excellent cosmetic results.[1]
SKIN: The Journal of Cutaneous Medicine (Jan 2025)
High freedom-from-recurrence: A multi-institutional study of thousands of lesions reported about 99% two-year freedom from recurrence with IG-SRT, with image guidance improving results over older superficial radiation.[2]
Multi-institutional IG-SRT cohort · PMID 40121415 (opens in a new tab)
DART clinical guidelines: The Dermatology Association of Radiation Therapy published guidelines detailing diagnosis, staging, and protocols for treating basal and squamous cell carcinoma with radiation, emphasizing a multidisciplinary approach.[3]
DART BCC/SCC guidelines
Common questions
Can skin cancer be treated without surgery? Yes. For many basal and squamous cell cancers, image-guided superficial radiation cures the cancer without cutting or stitches — especially valuable on the face, nose, ears, and eyelids.
Will I have a scar? Radiation leaves no surgical scar. The treated skin may look pink or dry for a few weeks and then heals, often with an excellent cosmetic result.
How many treatments will I need? Superficial radiation is typically given over several short visits across a few weeks; your plan depends on the tumor's size and location.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.
- SKIN: The Journal of Cutaneous Medicine (Jan 2025) (no indexed identifier — see your care team) ↩
- Moloney M, Harris PM, Kaczmarski P, Zheng S, Ladd D, Serure D, et al. Updated results of 3,050 non-melanoma skin cancer (NMSC) lesions in 1725 patients treated with high resolution dermal ultrasound-guided superficial radiotherapy, a multi-institutional study. BMC Cancer. 2025;25(1):526. (opens in a new tab) PMID 40121415 ↩
- DART BCC/SCC guidelines (no indexed identifier — see your care team) ↩